Yale University

EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale Medicine Thesis Digital Library

School of Medicine

1986

The role of left atrial chamber size as assessed by
echocardiography in determining thromboembolic
complications of atrial fibrillation
Cynthia Ann Hall
Yale University

Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl
Recommended Citation
Hall, Cynthia Ann, "The role of left atrial chamber size as assessed by echocardiography in determining thromboembolic
complications of atrial fibrillation" (1986). Yale Medicine Thesis Digital Library. 2684.
http://elischolar.library.yale.edu/ymtdl/2684

This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital
Platform for Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.

TI13
+Y1*

■■Mill

r-'

•xiv.-w ■-«.:■ «>:>»'»?;?>

THE ROLE OF LEFT A' •' " JHAMpER |ig|
AS ASSESSED BY ECHOQAROidGRAPHY^

Digitized by the Internet Archive
in 2017 with funding from
The National Endowment for the Humanities and the Arcadia Fund

https://archive.org/details/roleofleftatrialOOhall

The Role of Left Atrial Chamber Size
as Assessed by Echocardiography in Determining
Thromboembolic Complications of Atrial Fibrillation.

A Thesis Submitted to the Yale University
School of Medicine in Partial Fulfillment
of the Requirements for- the Degree of
Doctor of Medicine

by
Cynthia Ann Hall
1986

ACKNOWLEDEMENTS

I would like to thank
Dr. Henry S. Cabin
Assistant Professor of Medicine
Cardiology Section
for much enthusiasm, encouragement and guidance.

ABSTRACT

The Role of Left Atrial Chamber Size
as Assessed by Echocardiography in Determining
Thromboembolic Complications of Atrial Fibrillation

by
Cynthia Ann Hall
1986

To examine the usefulness of left atrial chamber size in
predicting patients at risk for thromboembolic complications
of atrial fibrillation without mitral stenosis, this study
examined 176 patients having atrial fibrillation without
mitral stenosis.

All patients had left atrial chamber size

measured by 2-D and M-Mode study.

Clinical charts were

reviewed for evidence of systemic embolization (central
nervous system, mesenteric and peripheral).

At the end of

the study period, 25/116 (22%) patients with left atrial
chamber size greater than or equal to 4.0cm as compared to
4/60(7%) patients with left atrial chamber size less than
4.0cm experienced a systemic embolism (p=.01).

Therefore

patients with atrial fibrillation without mitral stenosis
and left atrial chamber size greater than or equal to 4.0cm

have a 3 time greater embolic frequency than patients
with left atrial chamber size less than 4.0cm. Twenty-one of
ninety-eight (21%) of patients with underlying organic heart
disease embolized as compared to 8/78(10%) patients without
heart disease who embolized (p

< .05).

Patients with chronic

atrial fibrillation were more likely to embolize than those
with paroxysmal atrial fibrillation.

The risk of

embolization was not confined to any discrete time period
after the onset of atrial fibrillation.
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INTRODUCTION

In the 1950's systemic embolization was shown to be a serious
complication of atrial fibrillation when associated with mitral stenosis
(1).

Other researchers have since confirmed this finding (2,3,4).

Because these thromboembolic events may have devastating consequences
(5) efforts to prevent their occurrence are justified.

Although other

clinical entities associated with atrial fibrillation have been reported
to increase the risk of embolization (2,3,4), the only widely accepted
indication for anticoagulation in patients with atrial fibrillation is
the presence of mitral stenosis.

Unanswered questions regarding the

efficacy, duration and risk of anticoagulation therapy have resulted in
patients being untreated unless, the risk of embolization outweighed the
risk of anticoagulation therapy.

The incidence of spontaneous bleeding

ranges from less than 1% to almost 10% on heparin therapy and
complicates at least 5% of all courses of wafarin therapy, despite close
regulation (10).

Therefore, in this paper, patients with atrial

fibrillation without mitral stenosis were reviewed to assess their
overall risk of embolization and to identify any factors that could
increase or decrease their risk.

In particular, all patients underwent

an echocardiogram to assess the influence of left atrial chamber size on
embolic risk.

This study showed that patients with atrial fibrillation

without mitral stenosis and left atrial chamber size greater than or
equal to 4.0cm were at three times greater risk for embolization than

those with left atrial size less than 4.0cm.

Additionally, the presence

of underlying heart disease, chronic atrial fibrillation and increased
age significantly increased the embolic risk in the study population.

Clinical Materials and Methods

Patients with atrial fibrillation who underwent an
echocardiographic examination from January 1980 to December 1983 were
identified.

The period of time from the individual patient's

echocardiogram to December 1985 was considered the total period of this
study.

A diagnosis of atrial fibrillation was accepted only if

electrocardiographic evidence (6) or a physician's interpretation of an
electrocardiogram could be obtained from the patient charts.

Patients

with a clinical history of mitral stenosis were excluded as were
patients with echocardiographic evidence of mitral stenosis.

The

clinical, surgical, pathological and laboratory records were reviewed
for the following information:

age, sex, duration of atrial

fibrillation, duration of clinical follow-up after onset of atrial
fibrillation, echocardiographic determination of left atrial chamber
size (11), evidence of valvular disease (aortic stenosis, aortic
insufficiency, mitral regurgitation) (11), presence of coronary heart
disease, congestive heart failure, cardiomyopathy, diabetes mellitus,
hyperthyroidism, history of anticoagulation with wafarin, heparin, or
antiplatelet agents (Persantine and/or aspirin), history of tobacco or
alcohol use during period of study.

In addition, charts were reviewed

for evidence of systemic arterial embolic events.

(See the example of

the 3 page data collection form used for each patient, Fig. 4).

In

addition left atrial chamber size was determined by echocardiography in
each patient.

Of the 296 cases compiled, an attempt to establish

clinical follow-up with each patient was made.

The follow-up consisted

of a form letter mailed to the patient's last known address followed by

a phone call to determine if a systemic embolism had occurred.

The

letter informed the patient of the study and alerted the patient that a
follow-up phone call should be expected.

During the phone conversation,

the patient was asked about the use of anticoagulants, antiplatelet
agents, additional hospitalizations since the time of echocardiogram and
presence of symptoms consistent with an arterial embolic event. (See the
example of the one page patient letter and one page questionnaire, Fig.
2 and Fig. 3, respectively).

A total of 120 patients were excluded from

the 296 for the following reasons:

96 patients

No follow-up obtainable because
of death from unknown causes,
patient unavailable, or unwilling
to provide information.

19 patients

Simultaneous presentation of an
arterial embolic event and atrial
fibrillation

4 patients

Had prosthetic valve replacements
prior to or during study.

1 patient

Had peri-operative embolic event
during cardiac surgery and atrial
fibrillation could not be
documented prior to surgery.

TOTAL 120 patients excluded

The final number of confirmed cases of patients having atrial
fibrillation without mitral stenosis with adequate follow-up reviewed in
this study was 176.

Onset of Atrial Fibrillation:
The onset of atrial fibrillation was defined as the first
electrocardiographic evidence of atrial fibrillation present in the
patient chart or first documentation of atrial fibrillation by an
attending physician in the medical records.

Patients found to be in

atrial fibrillation for the first time when hospitalized for an embolic
event were excluded because it could not be determined whether atrial
fibrillation preceeded the embolic event.

Chronic vs Paroxsysmal Atrial Fibrillation:
A separation between chronic and paroxysmal atrial fibrillation was
made in this study.

Paroxysmal atrial fibrillation was defined as

patients whose medical records showed at least one spontaneous episode
of normal sinus rhythm after onset of atrial fibrillation during the
length of this study.

Chronic atrial fibrillation was defined as

patients with no documentation of spontaneous normal sinus rhythm after
the onset of atrial fibrillation with at least 2 electrocardiograms more
than one month apart.

Undetermined type of atrial fibrillation was

defined as patients with only 1 electrocardiogram in their medical
records or less than one month between two consecutive
electrocardiograms without spontaneous normal sinus rhythm.

■
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Definition of Arterial Embolic Event:
Cases were reviewed for presentations of clinical emboli which were
consistent with systemic arterial embolization.
subdivided into 3 categories:
peripheral events.

Embolic events were

central nervous system, mesenteric and

In addition, embolic events were categorized

according to correlation of clinical findings with laboratory findings.
The arterial embolic event was considered to be definite if CT scan,
angiographic or pathologic confirmation was available.

A probable

arterial embolic event lacked CT scan, angiographic and pathologic
confirmation but clearly demonstrated physical neurologic deficits
consistent with a cerebral vascular accident.

A possible arterial

embolic event was defined as a transient ischemic attack in the absence
of carotid artery disease.

a.

Cerebral vascular accident based on clinical diagnosis
with CT scan confirmation = Definite.

b.

Cerebral vascular accident based on clinical diagnosis
without CT scan confirmation = Probable.

c.

Transient ischemic attack in the absence of carotid artery
disease defined by absence of carotid bruits on physical
examination = Possible.

d.

Onset of painful/numb extremity and/or loss of pulse with
or without angiographic evidence of embolization resulting
in embolectomy = Definite.

e.

Clinical findings of mesenteric ischemia or infarction with
angiographic confirmation of embolization; liver, splenic
or renal infarction documented by liver/spleen scan or
renal angiography = Definite (27).

■

.

7

Embolic events occurring before the echocardiogram were not included
unless the patient experience a second event after the echocardiogram.
Pulmonary embolisms were not included in this study.

Echocardiographic Evaluation:
Echocardiographic examinations were performed in a routine fashion
with 2-D and M-Mode studies obtained in each patient.

Left atrial

chamber size was determined from the M-Mode study on each patient.

Definition of Cardiac Disease:
Non-Mitral Stenosis Valvular Disease:
In this study we excluded patients with clinical evidence of mitral
stenosis.

Patients with the following valvular lesions identified by

clinical assessment including echocardiogram were included:

aortic

stenosis, aortic insufficiency and mitral regurgitation.
Coronary Heart Disease:
Patients with a clinical history of ischemic cardiomyopathy, angina
and/or myocardial infarction confirmed by electrocardiographic findings
were included in this grouping.

One patient had a left ventricular

aneurysm detected by echocardiogaphy.
Other Heart Disease:
This group included patients with nonischemic cardiomyopathy with
ejection fraction

<45%, hypertrophic cardiomyopathy, congenital heart

disease, mitral valve prolapse, Sick-Sinus Syndrome and
Wolff-Parkinson-White Syndrome.
No Cardiac Disease:
Fhtients without any of the above mentioned cardiac abnormalities
were included in this group.

'
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Underlying Clinical Conditions:
Patient charts were screened for presence of the following clinical
conditions:

angina, myocardial infarction, hypertension,

hyperthyroidism, congestive heart failure and diabetes mellitus.

A

clinical history, laboratory values and/or x-ray studies were used to
establish the presence of these clinical processes.

History of Anticoagulation Therapy :
Patients were considered to be anticoagulated if they were on an
anticoagulant for greater than one month with therapeutic prothrombin
times (1.5 times the control).

In 4 patients the prothrombin times were

not available but the patient stated that they were being followed by a
physician and were told that their dose of anticoagulant was adequate.

Statistical Methods of Analysis:
The two-tailed test of significance and the nonparametric chi-square
test were employed to determine the statistical significance for this
study population.

RESULTS

Systemic Embolism:

The overall frequency of systemic arterial embolic events in
patients having atrial fibrillation without mitral stenosis was 29/176
(17%).

(See TABLE 1).

Of the 29 arterial embolic events, 12/29 (41%)

were definite, 14/29 (48%) probable and 3/29 ( 10%) were possible
embolic events according to the criteria of CT scan confirmation,
pathologic confirmation or embolectomy outlined in the methods.

Of the

total number of systemic arterial embolic events 24/29 (83%) involved
the brain, 4/29 (14%) were peripheral and 1/29 (3%) was a mesenteric
ischemic event.
The study population was divided into 4 groups to assess the
frequency of embolic events according to type and extent of underlying
heart disease:

valvular disease (excluding mitral stenosis), coronary

heart disease (ischemic cardiomyopathy, angina and/or myocardial
infarction), other heart disease (hypertrophic cardiomyopathy,
nonischemic cardiomyopathy, congenital heart disease, mitral valve
prolapse, Sick-Sinus Syndrome and Wolff-Parkinson-White Syndrome), and
combined heart diseases.

(See TABLE 2).

In patients with only valvular

heart disease 2/10 (20%) embolized, only coronary heart disease 10/65
(15%) embolized, only "other” heart disease 2/10 (20%) embolized and
with combined heart diseases 7/13 (54%) embolized.

There was no

significant difference between the embolic frequency of patients with
only valvular heart disease, coronary heart disease or "other" heart
disease.

However, the presence or absence of any of the defined heart

diseases was found to have a significant impact on embolic frequency.

.
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Twenty-one of ninety-eight (21%) patients with underlying heart disease
embolized as compared to 8/78 (10%) of those without heart disease
(P

<.05).

Duration of Atrial Fibrillation:
The mean length of time from echo to embolic event was 7 months (0
months - 45 months).

The patients without emboli were followed for a

mean of 35 months (0 days-71 months) from the time of echocardiography.
The mean duration of atrial fibrillation from onset to the end of
follow-up was 28 months (2 days-108 months) and 45 months (1 week - 228
months) in the embolic and nonembolic groups, respectively.

Of the 29

patients with embolic events, 4 (14%) had the event within 1 week of the
onset of atrial fibrillation, 4 (14%) from 2-4 weeks after the onset of
atrial fibrillation, 1 (3%) from 2-6 months, 10 (35%) from 7-24 months
and 10 (35%) from 3-9 years after the onset of atrial fibrillation. (See
Figure 5).

Chronic vs Paroxysmal Atrial Fibrillation:
The type of atrial fibrillation as defined in the methods section
proved to be an important influence on the frequency of embolic events.
Twelve of forty-one (29%) patients with chronic atrial fibrillation
embolized as compared to 13/104 (13%) of patients with paroxysmal atrial
fibrillation.
with P

<.02.

The difference between the frequencies was significant

Underlying Clinical Conditions:
The frequency of embolic events was similar in males and females.
The mean age of the embolic group was 75 years _+ 8.38 years as compared
to the mean age of the nonembolic group which was 70 years +_ 13.29 years
(P=.0346).

Four underlying clinical conditions were examined for their

possible influence on the frequency of embolic events.

Twelve of

seventy-three (16%) patients with congestive heart failure (CHF)
embolized compared to 17/103 (17%) patients without congestive heart
failure (P=NS).

Eighteen of twenty-four (21%) patients with

hypertension (HTN) embolized compared to 11/92 (.12%) patients without
hypertension (P=NS).

Eight of thirty-one (26%) patients with diabetes

mellitus embolized versus 21/145 (15%) of patients without diabetes
mellitus (P=NS).

Four of seventeen (24%) patients with hyperthyroidism

embolized versus 25/159 (16%) of patients without hyperthyroidism (P=NS).

Left Atrial Chamber Size:
The left atrial chamber sizes of the study population were divided
into 2 groups:
than 4.0cm.

chamber size greater than or equal to 4.0cm and less

A left atrial chamber size of 4.0cm or greater was chosen

to separate this population for analysis because 4.0cm exceeds the upper
limits of normal.

Left atrial chamber size of greater than or equal to

4.0cm proved to be a very significant risk factor for embolization.
Twenty-five of one-hundred and sixteen (22%) patients with left atrial
chamber size greater than or equal to 4.0cm embolized compared to 4/60
(7%) patients with left atrial chamber size less than 4.0cm (P=.01).
Thus, patients with left atrial chamber size greater than or equal to
4.0cm had 3 times the risk of embolization when compared to patients
with left atrial chamber size less than 4.0cm.

The mean left atrial

chamber size of the embolic group was 4.40cm _+ .54cm.

The mean left

atrial chamber size of the nonembolic group was 4.14cm +_ 1.03cm (P=NS).
(See Figure 1).

Anticoagulation Status:
During the follow-up process it was determined that five of one
hundred and seventy-six (3%) patients were chronically anticoagulated
for more than 2 years.
occur.

In none of these patients did an embolic event

Among the anticoagulated patients, the left atrial chamber size

did not differ from the remaining nonembolic patients.

Twenty-seven of

twenty-nine (93%) patients were anticoagulated or treated with
antiplatelet agents after the embolic event occurred.

In this study

patients were not analyzed for frequency of recurrent embolic events.

'

DISCUSSION

Atrial fibrillation is an idiopathic entity as well as a
complication of a variety of underlying cardiac diseases.

Atrial

fibrillation is seen in cardiac disease states such as Sick-Sinus
Syndrome, Wolff-Parkinson-White Syndrome, pericarditis, rheumatic heart
disease, coronary heart disease, mitral regurgitation, idiopathic
dilated cardiomyopathy hypertrophic and infiltrative cardiomyopathies.
In addition, atrial fibrillation is often seen in isolation with no
known cause.
Unfortunately, atrial fibrillation has been associated with
systemic embolization.

Therefore, a variety of investigators have

attempted to identify different clinical entities which increase a
patient's risk of embolization when associated with atrial
fibrillation.

Thusfar, the literature has identified the following

clinical entities:

mitral stenosis/rheumatic heart disease, ischemic

heart disease, hypertrophic cardiomyopathy and thyrotoxicosis.
Mitral stenosis and rheumatic heart disease have long been shown to
increase the embolic frequency in patients with atrial fibrillation.

In

1951, Daley reported the presence of mitral valve disease in 97% and
atrial fibrillation in 90% of his patients who experienced a systemic
embolism (16).

Szekely's series in 1964 identified mitral stenosis as a

risk factor for embolization by reporting a seven-times higher incidence
of embolization in patients with chronic rheumatic heart disease and
atrial fibrillation, than patients with chronic rheumatic heart disease
in normal sinus rhythm (14).

An autopsy series by Aberg in 1969

reported an embolic frequency of 53.5% in patients with atrial
fibrillation and valvular (including mitral stenosis) or congenital

heart disease.

He also reported an embolic frequency of 54.3% in

patients with atrial fibrillation and valvular disease combined with
ischemic heart disease (5).

In 1976, Henry et al also identified mitral

stenosis as a risk factor for embolization but, reported a much lower
frequency of embolization.

Twenty-six percent (22/85) of his study

population with mitral valve disease experienced a systemic embolic
event (8).

In 1977, Hinton’s autopsy series reported a 41% (29/70)

embolic frequency in patients with atrial fibrillation and mitral valve
disease (2).

In 1978, results of a study by Neilson et al paralleled

Henry's findings showing a 16.6% (37/234) embolic frequency among
patients with mitral stenosis (4).

The Framingham Study further

supported these findings by reporting a seventeen fold increase in
incidence of stroke among patients with chronic atrial fibrillation and
rheumatic heart disease (8).

Additionally, The Framingham Study

reported that the presence of chronic atrial fibrillation alone placed
patients at a five times greater risk for stroke than patients in normal
sinus rhythm.
Originally, ischemic heart disease was not considered to increase
the risk of embolization in patients with atrial fibrillation.

Early

autopsy studies by Beer and Ghitman in 1961 reported only a 2% (1/50)
incidence of embolization in patients with atrial fibrillation and
ischemic heart disease (7).
this finding.

However, Aberg's study in 1969 contradicted

Aberg reported a higher frequency of embolization in

patients with atrial fibrillation and valvular disease and ischemic
heart disease (5).

In 1977, Hinton et al divided patients into groups

having atrial fibrillation with mitral valve disease and atrial
fibrillation with ischemic heart disease.

Hinton reported a 35%

(59/171) incidence of embolization in patients with atrial fibrillation
and ischemic heart disease (2).

With the separation of atrial

fibrillation and ischemic heart disease from valvular disease, a risk of
embolization comparable to that seen in mitral stenosis could be made.
Consequently, recommendations for anticoagulation of this group were
made.
Although rare, hypertrophic cardiomyopathy has also been identified
as a risk factor which increases the embolic frequency in patients with
atrial fibrillation.

Henry et al reported a 25% (8/32) embolic

frequency among patients with atrial fibrillation and asymmetric septal
hypertrophy.
More recently, thyrotoxicosis has been associated with an increased
embolic frequency among patients with atrial fibrillation.

In 1980,

Bar-Sela et al reported a 40% (12/30) embolic frequency in patients with
thyrotoxicosis and atrial fibrillation (19).

None of the patients with

thyrotoxicosis without atrial fibrillation embolized (0/112).

However,

the authors note that the patients with atrial fibrillation had a higher
prevalence of rheumatic and hypertensive heart disease (19), of which
rheumatic heart disease is known to be an independent risk factor for
embolization.
In the majority of the studies discussed, no separation or
comparison between chronic and paroxysmal atrial fibrillation was made.
The Framingham Study included only patients with chronic atrial
fibrillation as defined by the presence of atrial fibrillation on
biennial examination (8).

Daley et al report that the majority of

embolic events in their study occur in chronic atrial fibrillation
versus paroxysmal atrial fibrillation but the definition of chronic and
paroxysmal atrial fibrillation is unclear (16).

Henry et al report that

91% of their embolic events occur in chronic atrial fibrillation which
they define as atrial fibrillation present at the time of echocardiogram

■

or if in sinus rhythm at the time of echocardiogram had a history of
atrial fibrillation lasting more than 24 hours requiring cardioversion
(3).

Reports by Beer and Ghitman, Szekely, Aberg, Hinton et al, Neilson

et al and Bar-Sela do not distinguish between the two types of atrial
fibrillation.
Despite other findings presented in the literature, it is still
generally accepted that only the combination of atrial fibrillation and
mitral stenosis poses a great enough risk of embolization to warrant
long-term anticoagulation therapy and its complications.

The present

study sets out to identify whether left atrial chamber size can be used
as a prognosticator of embolic risk in patients with atrial fibrillation
without mitral stenosis.

Systemic Embolism:
An attempt was made to subdivide systemic emboli into definite,
probable and possible according to laboratory information available to
correlate the clinical diagnosis.

Since the thrust of this study was to

assess the influence of left atrial size on embolic frequency, the mean
left atrial chamber sizes of the three subgroups were compared (P=NS).
Therefore it was assumed for the remainder of this study, that all
embolic events were correctly diagnosed regardless of ability to
correlate the clinical diagnosis with laboratory findings.

Thusfar, the

distinction between embolic and thrombotic cerebral vascular accidents
has been at best difficult, in all but autopsy reviews (17).

Like Wolf

et al in The Framingham Study, all strokes and transient ischemic
attacks are considered embolic in this study (8).

The overall frequency

of systemic embolization in patients with atrial fibrillation without
mitral stenosis was 29/176 (17%).

Eighty-three percent were cerebral

embolic events which is comparable to the previously reported frequency
of cerebral emboli among patients with embolic events (5).

Underlying Clinical Conditions:
The presence of any underlying cardiac abnormality made a
significant impact on embolic frequency in the study population.

The

presence of isolated non-mitral stenosis valvular disease or coronary
heart disease did not significantly increase the embolic frequency in
this study.

These findings contrast reports by Aberg, Coulshed and

Hinton of an increase embolic frequency in patients with valvular heart
disease or congenital heart disease combined with atrial fibrillation.
However, patients with the presence of any of the defined heart diseases
in this study had an increased embolic frequency as compared to patients
with no heart disease, 21/98 (21%) versus 8/78 (10%), respectively (P <
.05).

Multivariant analysis was not performed in this study.

Therefore

the effect of two or more underlying cardiac diseases on the embolic
frequency could not be assessed.

Chronic vs Paroxsysmal Atrial Fibrillation:
This study also shows that chronic atrial fibrillation is
associated with and increased frequency of embolization.

Twenty-nine

percent of patients with chronic atrial fibrillaiton embolized versus
13% of patients with paroxysmal atrial fibrillation (P

< 02).

Henry et

al reported that 91% (20/22) of their embolic events occurred in
patients with chronic atrial fibrillation (3).

Daley supports these

findings with his report that the majority of embolic events occurred
during chronic atrial fibrillation.

The Framingham Study only included

patients with chronic atrial fibrillation.

Few studies have attempted

■
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to distinguish between paroxysmal and chronic atrial fibrillation.

This

may be due to the difficulty of distinguishing between the presence of
paroxysmal or chronic atrial fibrillation without longterm cardiac
monitoring.

In this study chronic atrial fibrillation was defined by

the absence of documented spontaneous sinus rhythm on two separate
electrocardiograms one month or more apart.

Patients who were

chemically or electrically cardioverted were included in this group.

In

addition, it appears that not only the type of atrial fibrillation but
the timing of the embolic event may have implications for
recommendations of anticoagulation therapy.

Other researchers have

proposed that embolic events are most likely to occur in the first one
month to six months of atrial fibrillation (3).

The Framingham Study

failed to identify such a vunerable period in their review.

Although

the present study reports that 28% of embolic events occurred within one
month onset of atrial fibrillation, an additional 38% occur between 1
month and 24 months.

A total of 66% of the embolic events occurred

within 2 years of onset of atrial fibrillation.

Thus, when indicated,

anticoagulation therapy while important at the onset of atrial
fibrillation may be of benifit to patients found to be in atrial
fibrillation of longer duration.

Age:

The incidence of embolization was found to increase among patients
with increased age in this study population.

The embolic group had a

mean age of 75 years +_ 8 years compared to the nonembolic group mean of
70 years _+ 13 years (P=.03).

Coulshed and others have previously

reported an increased incidence of systemic embolization in persons with

increased age (15).
As detailed earlier, the identification of subgroups of patients at
risk for embolization with atrial fibrillation and other clinical
entites have rarely resulted in the widespread use of anticoagulation
therapy, except in the case of mitral stenosis.

The results of this

study also identify subgroups of patients at risk for embolization:
patients with underlying organic heart disease, chronic atrial
fibrillation and increased age.

However, the most important finding in

this study relates to left atrial chamber size and its ability to
predict patients at risk for systemic embolization.

Influence of Left Atrial Chamber Size:
This series shows that a left atrial chamber size of A.Ocm or more
is a very significant risk factor in patients having atrial fibrillation
without mitral stenosis.

The left atrial chamber measurements obtained

in the usual fashion using 2-D and M-mode echocardiography revealed that
25/116 (22%) patients with left atrial chamber size greater than or
equal to A.Ocm experienced a systemic arterial embolic event.

Four of

sixty (7%) patients with left atrial chamber size less than A.Ocm
embolized (P=.012A).

These results show that a patient with atrial

fibrillation without mitral stenosis with left atrial size greater than
or equal to A.Ocm is at 3 times greater risk for embolization than a
patient with left atrial size less than A.Ocm.

Left atrial chamber size

was determined on an average of 7 months (0 - A5 months) prior to
embolization.

Whether left atrial chamber size changes rapidly or

significantly in the absence of mitral stenosis remains undetermined.

.

20

A recently published abstract by D'Cruz et al reports that left
atrial dimensions determined by echocardiography were found to be
significantly larger in their embolic population.

Ninety percent of the

embolic group had enlarged left atrial size versus 20% of the nonembolic
group.

However, their study population was identified by the presence

of a stroke.

In their study population neither the onset of atrial

fibrillation nor the type of atrial fibrillation was known.
None of the embolic events occurred in patients on therapeutic
anticoagulation demonstrated by prothrombin times in the therapeutic
range (1.5 times control).

Patients who experienced embolic events were

not followed after their initial embolic event to assess the frequency
of recurrent embolic episodes.

The relative risk of embolization does

not increase as left atrial size increases suggesting a threshold effect
takes place near a chamber size of 4.0cm.

The embolic group did not

have many patients with left atrial chamber size greater than 5.0cm.
Therefore, the number of patients did not lend itself to rigorous
statistical analysis to challenge this possibility.
One major bias in this study is the identification of patients with
atrial fibrillation from a predominantly hospitalized population.
Ninety-six percent of the patients in this study had the initial
echocardiogram done as inpatients.

This may have selected for patients

with less ability to tolerate atrial fibrillation causing them to seek
medical attention for symptomatology.

Once these patients were

identified in an inpatient setting, echocardiography could be easily
obtained.

Conversely, patients who are asymptomatic and find out they

have atrial fibrillation on routine electrocardiogram may be less likely
to have echocardiography recommended as part of their work-up.

Conclusions:

Among patients with atrial fibrillation without mitral stenosis the
following conclusions are drawn:

1.

Patients with left atrial chamber size greater than or
egual to A.Ocm are significantly more likely to
embolize than patients with left atrial chamber size less
than 4.0cm.

2.

Patients with underlying organic heart disease compared to
those without underlying organic heart disease are more
likely to embolize.

3.

Patients with chronic atrial fibrillation are more likely
to embolize than those patients with paroxysmal atrial
fibrillation.

4.

The risk of embolization is not confined to any discrete
time period after the onset of atrial fibrillation.
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Legend

Figure 1
The blackened portion of the bar graph shows the percent of
patients with a given left atrial chamber size that embolize.

No patients

with left atrial chamber sizes less than 3.0cm or greater than 6.0cm
experienced and embolic event.
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Dear Mrs.

Philopence:

We are currently studying patients with an irregular heart beat who have
undergone an echocardiogram during 1980-1983 at Yale-New Haven Hospital.
At
some point during this time period,

your physician

'equested than an

echocardiogram (a test to evaluate the heart's chambers and valves) be
performed.
In the next several weeks, a member of our research staff will be
contacting you by telephone to ask you a few questions.
pertain to your present

state of

since you had an echocardiogram.

These questions will

health and medications you have
The

been taking

information gathered will not change

your present therapeutic regimen in any way.

The information gathered from

you will be combined with information from other patients with irregular heart
beats.

Please be assured that all information will remain confidential and

that you will not

be identified

by name in any reports of publications

resulting from this study.
We would appreciate your help in answering these questions which will
only take approximately 10 minutes of your time and can be done on the
telephone.
Your participation is voluntary and you may refuse to participate
or answer any particular questions without affecting future relationships with
physicians at Yale-New Haven Medical Center.
questions during our conversation.

Please feel free to ask any

Thank you in advance for your cooperation.
Sincerely,

/

i/.

/>,c (

Cynthia Hall, Medical Student
Yale University School of Medicine
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Atrial Fibrillation/Systemic Embolization Study
I.

Figure A

Personal Background

Name_Date of Birth_Sex_
Address___
Unit Number_Phone Number_Attending_
Date of Death_Cause_
II. Echo Data
Date_Reason_
LA Size_
Other Echo Findings_
III. Other Medical Problems
HTN

CHF

Tobacco

RHD

EtOH

Coronary Heart Disease

Hyperthyroidism

MI

AoV_MV_Prosthesis_

Date_

IV. Laboratory Tests and Interpretations
Index ECG Date_
LA Enlargement

Other Arrhythmias

LVH

MUGA Scan

MI

Index Chest X-Ray

V. Medical Management of Arrhythmias
DC Cardioversion

Inpatient Anticoagulation

Chemical Cardioversion

Outpatient Anticoagulation

Antiarrhythmics

Beginning of Outpatient Anticoagulation
type_

VI. Prothrombin Time Data
PT less than 1.5 time control
PT greater than or equal to 1.5-2 times control

VII. Atrial Fibrillation History
Date of ECG

Therapy

Drugs

A. Fib.

NSR

Other

.
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VII. Symptoms and/or Documentation of Embolization

CNS

Date of Embolization_
CT Scan Findings_
Angiogram Findings_
Autopsy Findings_
Clinical Findings on Physical Examination_

presence of absence of carotid artery disease

BOWEL

Date of Embolization
Pain Symptoms__
Angiogram Findings_
Autopsy Findings_
Clinical Findings_

OTHER ABDOMINAL FINDINGS

Date of Embolization_

Liver Infarction/Splenic Infarction/Kidney Infarction
Liver/Spleen Scan Findings_
EXTREMITY
Pain
Loss of Pulse
Angiogram Findings
Embolectomy Yes/No

.
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Figure 5
TIMING OF EMBOLIC EVENT AFTER ONSET OF ATRIAL FIBRILLATION
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Legend
Figure 5
This figure shows the distribution of embolic events according
to duration of atrial fibrillation.

Twenty-eight percent of the embolic

events occur within one month of onset of atrial fibrillation, 17% between
2 months and 12 months and 21% between 1 year and 2 years.

This shows

that the risk of embolization exist far longer than the 1-6 month period
of vunerability described by other authors (See Discussion).

35.

TABLE 1
EMBOLIC VS.. NONEMBOLIC GROUP
EMBOLIC

NONEMBOLIC

n=29

n=147

Mean 75YRS+8YRS

Mean 70YRS+13YRS

F

14(48%)

67(46%)

M

15(52%)

80(54%)

CHF

12(41%)

60(41%)

HTN

18(62%)

63(43%)

DIABETES

8(28%)

23(16%)

THYROID

4(14%)

13(9%)

CHD

17(59%)

61(42%)

VALVE DX

7(24%)

11(8%)

"OTHER"HD

4(14%)

18(12%)

NO HD

18(62%)

118(80%)

CHRONIC AF

12(41%)

29(20%)

PAROXY AF

13(45%)

91(62%)

AGE
SEX

UNDETERM AF 4(14%)

27(18%)

DURATION

Mean

OF AF
MTHS F/U

Mean
28mths (2days-108mths)
Thiths (0-45mths)

46mths (lwk-228mths)
35mths (0days-71mths)

% EMBOLIZATION
OF CHRONIC
PAROXY

12/41(29%)

0

13/104(13%)

0

UNDETERM 4/31(13%)

MEAN LA SIZE 4.40CM+.54CM

0

4.16CM+1.03CM
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TABLE 2
ORGANIC CARDIAC ABNORMALITIES
NON-MITRAL CORONARY

"OTHER"

COMBINED

NO HEART
DISEASE

STENOSIS

HEART

HEART

HEART

VALVE DX

DISEASE

DISEASE

DISEASE

n=10

n=6 5

n=10

n=l 3

AGE

-

-

-

-

n=78
-

TOTAL

n=176
71+13yrs

SEX F

6(60%)

22(34%)

5(50%)

6(50%)

42(54%)

81(46%)

M

4(40%)

43(66%)

5(50%)

7(54%)

36(46%)

95(54%)

CHF

4(40%)

36(55%)

7(70%)

6(46%)

19(24%)

72(40%)

HTN

6(60%)

33(50%)

5(50%)

6(46%)

31(40%)

81(46%)

DIABETES

0

19(29%)

1(10%)

2(46%)

9(12%)

31(18%)

1(10%)

8(12%)

0

0

8(10%)

17(10%)

CHRONIC AF

5(50%)

19(29%)

2(20%)

7( 54%)

8(10%)

41(23%)

PAROXY AF

5(30%)

37(57%)

4(40%)

5(39%)

55(71%)

104(59%)

9(14%)

4(40%)

1(8%)

15(19%)

31(18%)

2/5(40%)

4/19(21%)

0/2

3/7(43%)

3/8 (37%)

0/3

5/37(14%)

1/4(25%)

4/5(80%)

3/55(6%) 13/104(13%

1/9(11%)

1/4(25%)

0/1

2/15(13%) 4/31(13%)

HYPERTHYROID

UNDETERM AF 2(20%)
PERCENT
EMBOLIZATION
OF CHRONIC
PAROXY.

UNDETERM 0/2

12/41(29%)

EMBOLIC

2(20%)

10(15%)

2(20%)

7(54%)

8(10% )

29(17%)

NONEMBOLIC

8(80%)

55(87%)

8(80%)

6(46%)

70(90%)

147(84%)

cYAIi MEDICAL

YALE MEDICAL LIBRARY

3 9002 01005 0830

YALE MEDICAL LIBRARY
Manuscript Theses

Unpublished theses submitted for the Master’s and Doctor’s degrees and
deposited in the Yale Medical Library are to be used only with due regard to the
rights of the authors.
Bibliographical references may be noted, but passages
must not be copied without permission of the authors, and without proper credit
being given in subsequent written or published work.

This thesis by
has been
used by the following persons, whose signatures attest their acceptance of the
above restrictions.

NAME AND ADDRESS

DATE

